Fig 6. Concurrent loss of p53 does not modify the Recql4 phenotype.

(A) and (B): Primary long bone osteoblastic cells were derived from R26-CreER^T2 Recql4 p53 mice. They were then treated with tamoxifen and subjected to proliferation assays. n = 3–4 independent cultures per genotype; Data presented as mean±SEM. *P<0.05, **P<0.01, ***P>0.0005, ****P>0.00001 compared with vehicle, 2-way ANOVA. (C) The assessment of p53 genomic excision from tamoxifen-treated long bone osteoblastic cells from R26-CreER^T2 Recql4 p53 mice. Data presented as mean±SEM. (D) The assessment of Recql4 genomic excision from tamoxifen-treated long bone osteoblastic cells from R26-CreER^T2 Recql4 p53 mice.